Insider Selling: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) VP Sells 340 Shares of Stock

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) VP Lauren Bullaro Riker sold 340 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $43.70, for a total transaction of $14,858.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Pacira Pharmaceuticals, Inc. (PCRX) traded up $0.72 during midday trading on Thursday, hitting $42.22. 740,152 shares of the stock were exchanged, compared to its average volume of 693,299. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. The company has a market cap of $1,710.00, a P/E ratio of -32.23 and a beta of 2.20.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The company had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. During the same period in the previous year, the firm posted $0.20 EPS. The firm’s revenue was down 1.6% compared to the same quarter last year. sell-side analysts predict that Pacira Pharmaceuticals, Inc. will post -0.85 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp lifted its holdings in shares of Pacira Pharmaceuticals by 9.1% during the 2nd quarter. Northern Trust Corp now owns 505,529 shares of the company’s stock worth $24,114,000 after acquiring an additional 42,289 shares during the last quarter. State Street Corp lifted its holdings in shares of Pacira Pharmaceuticals by 1.0% during the 2nd quarter. State Street Corp now owns 1,118,083 shares of the company’s stock worth $53,340,000 after acquiring an additional 10,727 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Pacira Pharmaceuticals by 40.9% during the 2nd quarter. Baillie Gifford & Co. now owns 301,000 shares of the company’s stock worth $14,358,000 after acquiring an additional 87,400 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in shares of Pacira Pharmaceuticals by 40.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 191,224 shares of the company’s stock worth $9,121,000 after acquiring an additional 55,057 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its holdings in shares of Pacira Pharmaceuticals by 5.1% during the 2nd quarter. Stephens Investment Management Group LLC now owns 942,969 shares of the company’s stock worth $44,980,000 after acquiring an additional 45,514 shares during the last quarter.

PCRX has been the subject of a number of recent research reports. Bank of America reduced their price objective on shares of Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, October 4th. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a research note on Tuesday, October 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $44.00 price objective (down from $48.00) on shares of Pacira Pharmaceuticals in a research note on Sunday, October 1st. Needham & Company LLC reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Tuesday, September 26th. Finally, Mizuho reiterated a “buy” rating and issued a $53.00 price objective on shares of Pacira Pharmaceuticals in a research note on Monday, September 25th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. Pacira Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $49.00.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) VP Sells 340 Shares of Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/lauren-bullaro-riker-sells-340-shares-of-pacira-pharmaceuticals-inc-pcrx-stock.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply